Trial · NCT00710970

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

NCT00710970, Phase 2, Completed, Seth Lerner; results first posted 2013-08-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment. Trials, record NCT00710970. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00710970

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
NCT number: NCT00710970
Status: Completed
Phases: Phase 2
Enrollment: 28 participants, actual
Lead sponsor: Seth Lerner
Conditions: Urinary Bladder Neoplasms
Interventions: Tamoxifen
First posted: 2008-07-08
Last updated: 2022-01-24
Results first posted: 2013-08-22

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Freedom From Progression of Cancer at 4 Months	Estimated from date of starting therapy until 4 months but up to progression or death which ever comes first.	Clinical Assessments were performed every 4 weeks and imaging every 8 weeks or earlier if indicated. Patients were followed every month for clinical symptoms and signs of progression. Patients underwent Radiographic CT scans every 8 weeks to look for progression.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Freedom From Progression of Cancer at 4 Months	Estimated from date of starting therapy until 4 months but up to progression or death which ever comes first.		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants With Freedom From Progression of Cancer at 4 Months	Single Arm Receiving 25mg Tamoxifen		20		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Single Arm Receiving 20mg Tamoxifen	28
Overall Study	COMPLETED	Single Arm Receiving 20mg Tamoxifen	25
Overall Study	NOT COMPLETED	Single Arm Receiving 20mg Tamoxifen	3

Source ClinicalTrials.gov

Adverse events51

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Allergic Rhinitis	Immune system disorders	Single Arm Receiving 20mg Tamoxifen	1	19
other	anemia	Blood and lymphatic system disorders	Single Arm Receiving 20mg Tamoxifen	6	19
other	Decreased hematocrit	Blood and lymphatic system disorders	Single Arm Receiving 20mg Tamoxifen	5	19
other	Decreased hemoglobin	Blood and lymphatic system disorders	Single Arm Receiving 20mg Tamoxifen	4	19
other	Decreased lymphocytes	Blood and lymphatic system disorders	Single Arm Receiving 20mg Tamoxifen	4	19
other	Decreased Red Blood Cells	Blood and lymphatic system disorders	Single Arm Receiving 20mg Tamoxifen	1	19
other	Decreased White Blood Cells	Blood and lymphatic system disorders	Single Arm Receiving 20mg Tamoxifen	1	19
other	Increased Granulocytes	Blood and lymphatic system disorders	Single Arm Receiving 20mg Tamoxifen	1	19
other	Increased Monocytes	Blood and lymphatic system disorders	Single Arm Receiving 20mg Tamoxifen	1	19
other	Increased neutrophil	Blood and lymphatic system disorders	Single Arm Receiving 20mg Tamoxifen	1	19

1 to 10 of 51Source ClinicalTrials.gov

See all 51 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Single Arm Receiving 20mg Tamoxifen
Total, other adverse events	Single Arm Receiving 20mg Tamoxifen	18	19
Total, serious adverse events	Single Arm Receiving 20mg Tamoxifen	2	19

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
12084714	BACKGROUND	PubMed
16700038	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00710970

GET https://conductscience.org/api/trials/v1/NCT00710970/events?page=2

API reference For AI assistants